Evaluation of four monoclonal antibodies against HLA-B27 for their reliability in HLA-B27 typing with flow cytometry (FC): comparison with the classic microlymphocytotoxic test (MLCT).
Typing for HLA-B27 by serological methods is routinely performed using the microlymphocytotoxic test (MLCT). Since monoclonal antibodies (MAB) against HLA-B27 are available, flow cytometry (FC), which requires less time than the MLCT has been developed as an alternative technique. The aim of the present study was to check the accuracy and reliability of this method using different MAB against HLA-B27 in comparison to MLCT (using polyclonal antibodies against HLA-B27 and cross-reacting specificities [CRS]). FC was performed in 144 patients with HLA-B27-related rheumatic disorders (seronegative spondarthritides) using a special software package which requires corresponding calibration beads in order to achieve a standardized setup of the flow cytometer. MAB from the following producers were used: Becton & Dickinson (BD), Behringwerke (BE), One Lambda (OL), and Immunotech (IT). In addition to the critical limit of fluorescence intensity (FI) which indicates positivity if exceeded, provided by the software (but valid only for the MAB from BD), empirically twice the value of the STD calculated from the mean of the FI values of HLA-B27 positive patients was regarded a good cut off for the HLA-B27 positivity in FC measurements with the MAB used. Using a standard protocol including an incubation of whole EDTA-anticoagulated blood for 15 min with MAB against HLA-B27 (FITC-conjugated) and CD3 (PE-conjugated) and a lysis of erythrocytes, good discrimination between HLA-B27 positive and negative patients was obtained. Cross reactions with HLA-B27 positive patients occurred except when the MAB from OL was used. One false-negative result was found with OL's MAB (out of 22) and false-positive results occurred in HLA-B7+ patients when MAB from BD, BE, and IT were used. Unfortunately also 1 false-positive result (out of 57) was obtained in HLA-B7-, B27- patients with IT's MAB. Errors in the interpretation of the FC analysis might be avoided if more than one MAB (including those not cross reacting with HLA-B7) are used.
Neumüller
J
J
Ludwig Boltzmann Institute for Rheumatology and Balneology, Vienna, Austria.
Schwartz
D W
DW
Dauber
E
E
Mayr
W R
WR
D000911:Antibodies, Monoclonal; D000915:Antibody Affinity; D000918:Antibody Specificity; D000961:Antilymphocyte Serum; D015535:Arthritis, Psoriatic / Q000276:immunology; D016918:Arthritis, Reactive / Q000276:immunology; D003429:Cross Reactions; D003601:Cytotoxicity Tests, Immunologic; D005069:Evaluation Studies as Topic; D005434:Flow Cytometry; D015796:HLA-B27 Antigen / Q000276:immunology*; D015793:HLA-B7 Antigen / Q000276:immunology; D006650:Histocompatibility Testing / Q000592:standards; D006801:Humans; D007201:Indicator Dilution Techniques; D015203:Reproducibility of Results; D013167:Spondylitis, Ankylosing / Q000276:immunology; D013997:Time Factors
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D015796:HLA-B27 Antigen; D015793:HLA-B7 Antigen